Skip to content
Screener

Cerus CERS Q2 2026 earnings

Reported July 30, 2026 · After market close

Revenue$63.3MBeat by $400.0K
EPS-$0.01Beat by $0.00
Revenue estimate$62.9M
EPS estimate-$0.01
“I'm particularly pleased with the performance of our INTERCEPT Fibrinogen Complex (IFC) franchise in the U.S. The value proposition for blood centers, hospitals and clinicians is resonating and leading to earlier patient access to fibrinogen across the country. We view IFC as a compelling growth driver for Cerus.”
Vivek Jayaraman

Next report

Nov 2, 2026 (Today)
Revenue estimate$63.3M
EPS estimate-$0.01

Financials

Q2 2026

Income statement

See full
Revenue$57.4M—
Operating income-$1.9M+45.7%
Net income-$2.9M+48.5%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$18.0M+12.4%
Total debt$46.7M-34.0%
Total equity$70.0M+26.3%
Total assets$205.2M-3.7%

Cash flow

See full
Operating cash flow-$2.7M-8.8%
CapEx$873.0K+83.0%
Free cash flow-$3.5M-20.9%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$491.72M+83.2%
Enterprise value$520.45M+65.4%

Returns & leverage

See full
Return on equity-10.8%-4.5pp
Debt / equity0.7×-0.6×
Current ratio1.8×-0.2×

FAQ

When did Cerus report Q2 2026 earnings?
Cerus (CERS) reported Q2 2026 earnings on July 30, 2026 after market close.
What were Cerus's Q2 2026 revenue and EPS?
Cerus reported revenue of $63.3M and eps of $-0.01 for Q2 2026.
Did Cerus beat estimates in Q2 2026?
Revenue beat the consensus estimate of $62.9M by $400.0K. EPS beat the consensus estimate of $-0.01 by $0.00.
How did Cerus's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 20.7% from $52.4M a year earlier and eps grew 66.7% from $-0.03.
Where can I find Cerus's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-326093) and the 10-Q periodic report (0001193125-26-326295) directly on SEC EDGAR. The filing index links above go to sec.gov.